Title:
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADAM17 SUBSTRATE DEPENDANT CANCERS
Document Type and Number:
WIPO Patent Application WO/2016/102715
Kind Code:
A8
Abstract:
The present disclosure relates to the treatment of cancers and, more particularly, to the treatment of ADAM17 substrate dependant cancers which are refractory. The pharmaceutical composition contains an ADAM17 antibody (it recognizes an epitope within the membrane proximal domain of ADAM17 localized between the residues 564 and 642) characterized by the sequences of its variable chains.
Inventors:
LOWE PETER (FR)
BOUTE NICOLAS (FR)
JOUHANNEAUD ALEXANDRA (FR)
BOUTE NICOLAS (FR)
JOUHANNEAUD ALEXANDRA (FR)
Application Number:
PCT/EP2016/050028
Publication Date:
March 16, 2017
Filing Date:
January 04, 2016
Export Citation:
Assignee:
PF MEDICAMENT (FR)
International Classes:
A61K39/395; A61P35/00; C07K16/28; C07K16/40; A61K39/00
Attorney, Agent or Firm:
REGIMBEAU (FR)
Download PDF:
Previous Patent: PROCESS FOR MAKING A VISCOUS COMPOSITION COMPRISING WHEY PROTEIN
Next Patent: NOVEL HUMANIZED ADAM17 ANTIBODY
Next Patent: NOVEL HUMANIZED ADAM17 ANTIBODY